DrugPatentWatch Database Preview

Details for Patent: 7,832,351

Which drugs does patent 7,832,351 protect, and when does it expire?

Patent 7,832,351 protects ADVAIR HFA, FLOVENT HFA, and VENTOLIN HFA, and is included in three NDAs.

Protection for ADVAIR HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-four patent family members in seventeen countries.

Summary for Patent: 7,832,351

Title:	Actuation indicator for a dispensing device
Abstract:	An actuation indicator which includes a drums sub-assembly including a rotatable actuation indicator wheel, a rocking ratchet pawl for rotating the indicator wheel in a set direction and a rocking mechanism for the pawl driven by a slipping clutch arrangement, wherein the slipping clutch arrangement includes a slipping clutch spring engaged at one end to a pinion of a rack and pinion assembly and at a second end to the ratchet pawl is described.
Inventor(s):	Bonney; Stanley George (Ware, GB), Brand; Peter John (Ware, GB), Godfrey; James William (Ware, GB), Rand; Paul Kenneth (Ware, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	12/333,420
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,832,351
Patent Claim Types: see list of patent claims	Device; Delivery;

Drugs Protected by US Patent 7,832,351

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-002	Jun 8, 2006		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-003	May 14, 2004		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,832,351

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,500,444	Actuation indicator for a dispensing device	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,832,351

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	424010	➤ Sign Up
Australia	2003278236	➤ Sign Up
Brazil	0311557	➤ Sign Up
Canada	2489554	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,832,351

For more information try a trial or see the plans and pricing